Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.15, read 2026-11-05
Ethical passes the values gate
Price19.21 USD
Fair value14.98
Ethical score70.0/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-04Read Distribution18.99+1.2% to today Accumulation gives way to Distribution
2026-10-28Read Accumulation19.68-2.4% to today Markdown gives way to Accumulation
2026-10-21Read Markdown19.75-2.7% to today ✓Markup gives way to Markdown after a 35% rise in 16 weeks
2026-07-02Read Markup14.62+31.4% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
SailPoint, Inc. holds its Distribution at $19.21. The statistical read favours the buyers, held for 5 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 5 days
Price at the screen
$19.21
Valuation
N/A trailing · 48.94 forward price to earnings
Values screen
PASS· score 70.0
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.24%
Below 33%
Interest-bearing debt is just 0.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.12%
Below 49%
Money owed to the company is 9.1% of assets, under the 49% limit.
Pass
Revenue purity
1.01%
Below 5%
Only 1.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
SailPoint, clears all five screens. Its business is in a permissible area, its debt is near-nil, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SAIL's ethical verdict changes
Today SAIL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $14.98 fair value estimate, 16.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 28.2% above the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +15% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $14.98, with a range of $9.19 to $17.23, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Digital identity guard priced past its profits
Picture a company selling the keys to every corporate door, yet still losing money on each one sold. SailPoint sells identity security tools that let firms control who gets in and what they can touch across regions. The business grows revenue at 22 percent, clears the ethical screen, and draws buy ratings from two dozen analysts with a median target near 19 dollars. Yet at 15.68 the shares sit above our fair value of 14.12, and none of that growth has turned into profit.
Forward earnings sit at 39 times while margins run at minus 14 percent and return on equity is minus 2 percent. Those figures show a firm still investing heavily without clear returns. The unknown moat leaves open the question of whether rivals can copy the offering faster than SailPoint can widen its lead.
High multiples on negative earnings often signal peak optimism rather than durable advantage. Currency swings and slower enterprise spending could widen the gap between price and value further. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SAIL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. Insiders have been net sellers over the past quarter.
2026-10-21Markdown · changed$19.75-4.9%Entry 14
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. Insiders have been net sellers over the past quarter.
2026-10-14Markup$20.77+2.2%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. Insiders have been net sellers over the past quarter.
2026-10-02Markup$20.32-0.6%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18.
2026-09-09Markup$20.45+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-08Markup$20.45+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-06Markup$20.45+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-05Markup$20.45+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-04Markup$20.45+0.0%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (24 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
